[1]Medical Center of Fudan University, Institute of Antibiotics,Shanghai,China
[2]Shanghai Second Medical University,Shanghai,China
[3]The First Affiliated Hospital of Kunming Medical University, Department of Laboratory Medicine,Kunming,China
To evaluate the efficacy and safety of domestic aztreonam on the treatment of Gram-negative bacterial infections, 71 cases of respiratory, urinary, intra-abdominal, soft tissue and skin infections and septicemia were treated with domestic aztreonam, as well as a randomized controlled study was carried out in 64 cases of respiratory and urinary tract infections with domestic aztreonam vs imported one. Total effective and bacterial eradication rates were 88.7% and 87% for domestic aztreonam respectively, adverse reaction occurred in 2.1% of patients. Results of the randomized controlled study showed that the effective, bacterial eradication and adverse reaction rates were comparable in two groups. Results of the MIC demonstrated that aztreonam was highly active against E. coli, K. pneumoniae and other Enterobacteriaceae, similar to those of the 3rd generation cephlosporins, amikacin and ciprofloxacin, and superior to that of ciprofloxacin for E. coli. Conclusion: domestic aztreonam is effective for the treatment of infections caused by Gram-gegative bcateria and the adverse reaction of the drug is rare and mild. The efficacy and safety of the domestic aztreonam are similar to those of imported one.
(8.0+极速模式)